Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

8 hours BMP6 treated vs untreated human mesenchymal stem cells (hMSC)

ABSTRACT: We have established that BMP6 is an important endogenous regulator of human osteoblast differentiation. Our preliminary experiment showed that 8 hour BMP6 treatment induced early osteoblast markers in hMSC. In this study, we used microarrays to profile the global gene expression program in hMSC induced by BMP6 treatment and further identify the early osteogenic responses to BMP6 stimulation. Keywords: Stress response

ORGANISM(S): Homo sapiens

PROVIDER: GSE13604 | GEO | 2009/06/01

SECONDARY ACCESSION(S): PRJNA110225

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Transcription profiling of human mesenchymal stem cells treated for 8 hours with BMP6

Project description:We have established that BMP6 is an important endogenous regulator of human osteoblast differentiation. Our preliminary experiment showed that 8 hour BMP6 treatment induced early osteoblast markers in hMSC. In this study, we used microarrays to profile the global gene expression program in hMSC induced by BMP6 treatment and further identify the early osteogenic responses to BMP6 stimulation. Experiment Overall Design: The dataset contains a total of 4 gene chip measurements from duplicate experiments each with paired measurements of human MSC with or without 8 hours BMP6 treatment.

2009-06-08 | E-GEOD-13604 | biostudies-arrayexpress

A time series study on BMP6 induced osteoblast differentiation of human mesenchymal stem cells (hMSC)

Project description:BMP6 mediated osteoblast differentiation plays a key role in skeletal development and bone disease. Unfortunately, the signaling pathways regulated by BMP6 are largely uncharacterized due to both a lack of data and the complexity of the response. To better characterize the signaling pathways responsive to BMP6, we conducted a time series microarray study to track BMP6 induced osteoblast differentiation and mineralization. Human MSC cells underwent osteogenic induction with BMP6 treatment for 0 hours, 8 hours, 24 hours, and 96 hours, which correspond to four phenotypic groups, i.e. control, preosteoblast (no mineralization), (sub-maximal) mineralization, and maximal mineralization at 14 days after the initiation of BMP treatment (18 days in total). Cells were harvested at 8 hours, 24 hours, 96 hours and 10 days for microarray profiling. Assays were run in duplicate for a total of 26 arrays. We only used 20 arrays in the reference paper.

2011-09-19 | E-GEOD-28074 | biostudies-arrayexpress

A time series study on BMP6 induced osteoblast differentiation of human mesenchymal stem cells (hMSC)

2011-09-20 | GSE28074 | GEO

Expression data from hMSC-TERT4 cells during osteoblast differentiation

Project description:Differentiation of human skeletal stem cells (hMSC) into osteoblasts is regulated by a few well described transcription factors. Our study used clustering and gene expression data to identify a novel transcription factor. ZNF25, which we showed is involved in osteoblast differentiation. We used microarrays to study gene expression of hMSC-TERT4 cells during osteoblast differentiation.

2016-09-01 | GSE83971 | GEO

Expression data from hMSC-TERT4 cells after siZNF25 knockdown

2016-09-01 | GSE83901 | GEO

Expression profiling of LINC01638 interference in hMSC-hTERT20 cells

Project description:We identified LINC01638 as a lncRNA that is highly expressed in proliferating MSCs and decreases in expression during osteogenesis. We demonstrate that knockdown of LINC01638 in hMSC-hTERT20 cells by CRISPRi during osteogenic differentiation causes an decrease in alkaline phosphatase (ALP) activity and ALPL gene expression. Altered expression of several extracellular matrix proteins was noted. We identified LINC01638 as a nuclear lncRNA that binds to chromatin and where it regulates gene expression. These results reveal that LINC01638 may act as a negative regulator of osteoblast differentiation, thereby providing a novel mechanism of regulatory control of osteogenesis.

2023-12-07 | GSE227512 | GEO

Expression profiling of MIR181A1HG interference in hMSC-hTERT20 cells

Project description:We identified MIR181A1HG as a lncRNA that is ubiquitously expressed in non-mineralized tissues, highly expressed in proliferating MSCs and decreases in expression during osteogenesis. We demonstrate that knockdown of MIR181A1HG in hMSC-hTERT20 cells by CRISPRi during osteogenic differentiation causes an increase in alkaline phosphatase (ALP) activity and ALPL gene expression. Increased expression of several extracellular matrix proteins was noted. We identified MIR181A1HG as a nuclear lncRNA that binds to chromatin and where it regulates gene expression, including the transcription factor SOX5. These results reveal that MIR181AHG may act as a negative regulator of osteoblast differentiation, thereby providing a novel mechanism of regulatory control of osteogenesis.

2022-05-18 | GSE184087 | GEO

Gene expression analyses of the differentiating hMSC into Osteoblasts and Adipocytes.

Project description:Age-related skeletal degeneration in patients with osteoporosis is characterized by decreased bone mass and occurs concomitant with an increase in bone marrow adipocytes. Using microarray expression profiling with high temporal resolution, we identified gene regulatory events in early stages of osteogenic and adipogenic lineage commitment of human mesenchymal stromal cells (hMSCs). Data analysis reveal three distinct phases when cells adopt a committed expression phenotype: initiation of differentiation (0-3h, Phase I), lineage-acquisition (6-24h, Phase II) and early lineage-progression (48-96h, Phase III). Upstream regulator analysis identifies 34 transcription factors (TFs) in Phase I with a role in hMSC differentiation. Interestingly, expression levels of identified TFs did not always change and indicate additional post-transcriptional regulatory mechanisms. Functional analysis reveals that forced expression of IRF2 enhances osteogenic differentiation. Thus, IRF2 and other ‘early-responder‘ TFs may control osteogenic cell fate of MSCs and should be considered in mechanistic models that clarify bone-anabolic changes during clinical progression of osteoporosis.

2017-03-15 | GSE80614 | GEO

Transcription profiling of human bone marrow mesenchymal stromal cells before and after stimulation with dexamethasone to study the early molecular processes of osteogenic differentiation

Project description:Human adult mesenchymal stromal cells (hMSC) have the potential to differentiate into chondrogenic, adipogenic or osteogenic lineages, providing a potential source for tissue regeneration. An important issue for efficient bone regeneration is to identify factors that can be targeted to promote the osteogenic potential of hMSCs. Using transcriptomic analysis, we found that integrin alpha5 (ITGA5) expression is upregulated during dexamethasone-induced hMSCs osteoblast differentiation. Gain-of-function studies showed that ITGA5 promotes the expression of osteoblast phenotypic markers as well as in vitro osteogenesis in hMSCs. Downregulation of endogenous ITGA5 using shRNA blunted osteoblast marker expression and osteogenic differentiation. Pharmacological and molecular analyses showed that the enhanced hMSCs osteoblast differentiation induced by ITGA5 was mediated by activation of FAK/ERK1/2-MAPKs and PI3K signaling pathways. Remarkably, activation of ITGA5 using a specific antibody that primes the integrin or a peptide that specifically activates ITGA5 was sufficient to enhance ERK1/2-MAPKs and PI3K signaling and to promote osteoblast differentiation and osteogenic capacity of hMSCs. We also demonstrate that hMSCs engineered to over-express ITGA5 exhibited a marked increase in their osteogenic potential in vivo. These findings not only reveal that ITGA5 is required for osteoblast differentiation of adult human MSCs but also provide a novel targeted strategy using ITGA5 agonists to promote the osteogenic capacity of hMSCs, which may be used for tissue regeneration in bone disorders where the recruitment or capacity of MSCs is compromised. Experiment Overall Design: Gene expression profiles were generated from bone marrow MSC before and 1, 3 and 7 days after stimulation with 10E-7M dexamethasone to study the early molecular processes of osteogenic differentiation. 3 replicates per timepoint.

2009-09-18 | E-GEOD-18043 | biostudies-arrayexpress

Expression data from hMSC-TERT4 cells after during osteoblast differentiation

2016-09-01 | GSE84034 | GEO